Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol

BACKGROUND: Despite effective treatments, metastatic colorectal cancer (mCRC) prognosis is still poor, mostly in RAS-mutated tumors, thus suggesting the need for novel combinatorial therapies. Epigenetic alterations play an important role in initiation and progression of cancers, including CRC. Hist...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Ther Adv Med Oncol
Huvudupphovsmän: Avallone, Antonio, Piccirillo, Maria Carmela, Di Gennaro, Elena, Romano, Carmela, Calabrese, Filomena, Roca, Maria Serena, Tatangelo, Fabiana, Granata, Vincenza, Cassata, Antonio, Cavalcanti, Ernesta, Maurea, Nicola, Maiolino, Piera, Silvestro, Lucrezia, De Stefano, Alfonso, Giuliani, Francesco, Rosati, Gerardo, Tamburini, Emiliano, Aprea, Pasquale, Vicario, Valeria, Nappi, Anna, Vitagliano, Carlo, Casaretti, Rossana, Leone, Alessandra, Petrillo, Antonella, Botti, Gerardo, Delrio, Paolo, Izzo, Francesco, Perrone, Francesco, Budillon, Alfredo
Materialtyp: Artigo
Språk:Inglês
Publicerad: SAGE Publications 2020
Ämnen:
Study Protocol
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7425244/
https://ncbi.nlm.nih.gov/pubmed/32849914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920929589
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk